CF patients with at least one mutation that retains a residual channel activity could be treated with a strategy that aims to stabilize the CFTR messenger RNA (mRNA), thus increasing the amount of the protein and resulting in a net chloride flux increase [3]. Here, CFTR is linked to cystic fibrosis.